Newsroom

Download PDF Results Show Median Progression-Free Survival of 11.8 Months; Tivozanib Designated as Generic Name for AV-951 CAMBRIDGE, Mass., May 29, 2009> – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced additional data from its Phase 2 clinical trial of tivozanib

Download PDF Progression-free Survival Data from AV-951 Phase 2 Trial in Advanced Kidney Cancer to be Highlighted at ASCO CAMBRIDGE, Mass., May 18, 2009– AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that the company will be participating in several upcoming

Download PDF SAB Members Elected to NAS and IOM; Honored with Awards from AACR and NFCR CAMBRIDGE, Mass., May 13, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that members of its Scientific Advisory Board (SAB) have been newly

Download PDF Data Presented at AACR Annual Meeting; Suggests Additional Therapeutic Potentialfor AV-951 DENVER, Col., April 21, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced data from its proprietary preclinical models which demonstrates that the company’s potent and selective

Download PDF FGFR-2 Target Identification and Response Data Also Highlighted; Data Presented at AACR Annual Meeting DENVER, Col, April 19, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today presented a novel human hepatocyte growth factor (HGF) knock-in model and announced

Download PDF CAMBRIDGE, Mass., April 9, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that it will present during two educational sessions, nine poster sessions and a minisymposium at the American Association for Cancer Research (AACR) 100th Annual Meeting

Download PDF AVEO Scientists Generate Human Tumors in Mice from Primary Human Breast Tissue; Provides More Realistic Genetic Context in which to Evaluate New Anti-tumor Therapies CAMBRIDGE, Mass., April 6, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced findings

Download PDF CAMBRIDGE, Mass., March 26, 2009 – AVEO Pharmaceuticals, Inc. today announced that Elan Ezickson, chief business officer, is scheduled to present at the Future Leaders in the Biotech Industry Conference on Thursday, April 2, 2009 at 1:30 p.m. (EDT) at the Millennium Broadway Hotel & Conference Center in New York City. About AVEO